Silo Pharma Finalizes Sublicense Deal for its Targeted Psilocybin Cancer Therapeutic Technology (SILO)
Agreement to explore the use of Silo Pharma’s Novel Peptide Englewood Cliffs, NJ, April 07, 2021 (GLOBE NEWSWIRE) — Silo
Read moreAgreement to explore the use of Silo Pharma’s Novel Peptide Englewood Cliffs, NJ, April 07, 2021 (GLOBE NEWSWIRE) — Silo
Read moreNewsfile Corp.Newsfile Corp Phoenix, Arizona–(Newsfile Corp. – January 20, 2021) – The Stock Day Podcast welcomed Silo Pharma Inc. (OTCQB:
Read moreEnglewood Cliffs, NJ, Jan. 11, 2021 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on
Read more